Humoral response—univariate and multivariate analyses
| (A) Univariate analyses | |||
| Humoral response | Positive | Negative | P value |
| Age mean(SD) | 56.9 (13.3) | 62.05 (11.6) | 0.024 |
| Gender —female | 157 | 27 | 0.64 |
| Disease duration mean (SD) | 10.7(7.3) | 13.2(7.3) | 0.032 |
| Type of rheumatic disease | |||
| IJD | 135 | 17 | 0.277 |
| CTD | 70 | 17 | |
| Vasculitis | 17 | 2 | |
| Other | 5 | 1 | |
| Therapy, n | |||
| None | 22 | 0 | 0.052 |
| csDMARDs | 136 | 24 | 0.567 |
| Methotrexate | 68 | 10 | 0.717 |
| Mycophenolate mofetil | 17 | 9 | 0.004 |
| Biological/targeted DMARDs | 148 | 30 | 0.056 |
| B-cell depleting (Anti-CD-20) | 24 | 24 | 0.0001 |
| Belimumab | 9 | 2 | 0.656 |
| Anti-TNF anti-interleukins abatacept | 63 39 5 | 0 1 3 | 0.02 0.023 0.086 |
| Anti-JAK agents | 9 | 0 | 0.618 |
| Combined therapy (without rituximab) | 65 | 5 | 0.043 |
| Corticosteroids | 76 | 16 | 0.248 |
| (B) Multivariate logistic regression analysis | |||
| Variables | P value | OR | 95% CI lower to upper |
| Age | 0.084 | 0.965 | 0.927 to 1.005 |
| Disease duration | 0.043 | 0.948 | 0.900 to 0.998 |
| MMF | 0.0001 | 0.064 | 0.017 to 0.239 |
| Anti-CD20 | 0.0001 | 0.033 | 0.012 to 0.092 |
| Abatacept | 0.003 | 0.07 | 0.012 to 0.399 |
csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; CTD, connective tissue diseases; IJD, inflammatory joint diseases; JAK, janus kinase; MMF, mycophenolate mofetil.